We investigated the influence of the HIV infection on serum paraoxonase-3 (PON3) concentration and assessed the relationships with lipoprotein-associated abnormalities, immunological response, and accelerated atherosclerosis. We studied 207 HIV-infected patients and 385 healthy volunteers. Serum PON3 was determined by inhouse ELISA, and PON3 distribution in lipoproteins was investigated by fast-performance liquid chromatography (FPLC). Polymorphisms of the PON3 promoter were analyzed by the Iplex Gold MassArrayTM method. PON3 concentrations were increased (about three times) in HIV-infected patients with respect to controls ( P < 0.001) and were inversely correlated with oxidized LDL levels ( P = 0.038). Long-term use of nonnucleoside reverse transcriptase inhibitor (NNRTI)-based antiretroviral therapy was associated with a decrease of PON3 concentrations. In a multivariate linear regression analysis, these relationships were still strong when the main confounding covariates were considered. PON3 was mainly found in HDL in HIV-infected patients, but a substantial amount of the protein was detected in LDL particles. This study reports for the first time an important increase in serum PON3 concentrations in HIV-infected patients that is associated with their oxidative status and their treatment with NNRTI. Long-term, prospective studies are needed to confirm the possible influence of this enzyme on the course of this disease and its possible utility as an analytical biomarker. Copyright © 2012 by the American Society for Biochemistry and Molecular Biology, Inc.
CITATION STYLE
Aragonès, G., García-Heredia, A., Guardiola, M., Rull, A., Beltrán-Debón, R., Marsillach, J., … Camps, J. (2012). Serum paraoxonase-3 concentration in HIV-infected patients. Evidence for a protective role against oxidation. Journal of Lipid Research, 53(1), 168–174. https://doi.org/10.1194/jlr.P018457
Mendeley helps you to discover research relevant for your work.